We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+14.35%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.65B
AUM Growth
+$205M
Cap. Flow
-$69.3M
Cap. Flow %
-2.62%
Top 10 Hldgs %
39.13%
Holding
181
New
13
Increased
25
Reduced
35
Closed
9

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$17.1M
2
PFE icon
Pfizer
PFE
+$15.6M
3
BIIB icon
Biogen
BIIB
+$14.1M
4
MCK icon
McKesson
MCK
+$12.2M
5
AVTR icon
Avantor
AVTR
+$9.51M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.5M
2
JNJ icon
Johnson & Johnson
JNJ
+$24.9M
3
HUM icon
Humana
HUM
+$18.5M
4
AZN icon
AstraZeneca
AZN
+$15.7M
5
MOH icon
Molina Healthcare
MOH
+$15.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.55%
2 Real Estate 1.68%
3 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRTX
126
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$1.34M 0.05%
898,374
– –
PTGX icon
127
Protagonist Therapeutics
PTGX
$8.66B
$1.33M 0.05%
+122,271
New +$1.03M
ZLAB icon
128
Zai Lab
ZLAB
$2.08B
$1.33M 0.05%
43,300
– –
STVN icon
129
Stevanato
STVN
$5.42B
$1.28M 0.05%
71,190
– –
MORF
130
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$1.19M 0.05%
44,625
– –
STRO icon
131
Sutro Biopharma
STRO
$425M
$1.19M 0.05%
14,753
-1,639
-10% -$114K
MREO
132
Mereo BioPharma
MREO
$52M
$1.16M 0.04%
1,551,082
– –
ACAD icon
133
Acadia Pharmaceuticals
ACAD
$4.47B
$1.15M 0.04%
72,225
– –
SRRK icon
134
Scholar Rock
SRRK
$5.7B
$985K 0.04%
108,833
– –
PYXS icon
135
Pyxis Oncology
PYXS
$202M
$949K 0.04%
708,303
– –
CRNX icon
136
Crinetics Pharmaceuticals
CRNX
$8.91B
$839K 0.03%
+45,861
New +$808K
ALXO icon
137
ALX Oncology
ALXO
$269M
$746K 0.03%
66,211
– –
AFMD
138
DELISTED
Affimed
AFMD
$727K 0.03%
58,604
– –
PLRX icon
139
Pliant Therapeutics
PLRX
$65M
$681K 0.03%
+35,233
New +$737K
NBP
140
NovaBridge Biosciences American Depositary Shares
NBP
$193M
$680K 0.03%
162,580
– –
NVAX icon
141
Novavax
NVAX
$1.25B
$656K 0.02%
63,800
– –
ICPT
142
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$644K 0.02%
52,067
– –
BEAM icon
143
Beam Therapeutics
BEAM
$2.85B
$619K 0.02%
15,817
– –
UHT
144
Universal Health Realty Income Trust
UHT
$588M
$537K 0.02%
11,258
– –
CHCT
145
Community Healthcare Trust
CHCT
$513M
$533K 0.02%
14,900
– –
NHI icon
146
National Health Investors
NHI
$3.62B
$524K 0.02%
10,038
– –
ONEM
147
DELISTED
1Life Healthcare
ONEM
$522K 0.02%
31,266
– –
THRX
148
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$498K 0.02%
100,000
– –
BHVN icon
149
Biohaven
BHVN
$2.03B
$487K 0.02%
+35,087
New +$495K
RPTX
150
DELISTED
Repare Therapeutics
RPTX
$429K 0.02%
29,150
– –
4 5
6
7 8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Tekla Capital Management held 181 positions worth $2.65B, up 8.4% from $2.44B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q4 2022 filing shows 13 new, 25 increased, 35 reduced and 9 closed positions. Its largest new stake was Avantor: 459,488 shares worth $9.69M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $26.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q4 2022 buy was Avantor: 459,488 shares worth $9.69M.
  • Tekla Capital Management added most to Eli Lilly in Q4 2022, an estimated $17.1M increase.
  • Tekla Capital Management's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $26.5M.
  • Tekla Capital Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $10.6M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.65B portfolio in Q4 2022.
  • Tekla Capital Management opened 13 new positions and closed 9 in Q4 2022.
  • Tekla Capital Management's portfolio value rose 8.4% quarter-over-quarter to $2.65B.

Based on Tekla Capital Management's 13F filing for Q4 2022, filed 10 Feb 2023.